EDITORIAL SECTION
-
STRATEGY
Smarter Pharma
Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solution
-
CLINICAL TRIALS
Why Clinical Trials Need Digital Endpoints
According Citeline the average success rate for bringing a Phase candidate to market has dropped to an alltime low of just
-
MANUFACTURING
Ensuring Quality and Compliance in Biopharma
Ensuring quality and regulatory compliance in the biopharmaceutical industry is critical to safeguarding product safety and efficacy
-
Information Technology
The Cost of Bad Data
Modern pharmaceutical research generates an unprecedented volume of information Data from genomic sequencing
-
Biopharma
Reimagining Global Biomanufacturing Capacity with Continuous and Modular Systems
Biotechnology is fueling the ongoing expansion of the global market for a broad array of goods
-
EXPERT Talk
Compliance to Competitive Advantage in Pharma Supply
Compliance gets you through an audit Resilience gets medicines to patients on the day something unexpected happens The DSCSAs enhanced requirements took effect November but real interoperability required three more rounds of accommodation phased implementation with the smalldispenser
Advisory Board
KNOWLEDGE BANK
-
Articles
Rethinking Make-or-Buy: Strategic Manufacturing Decisions in Pharma
Few strategic decisions in pharmaceutical operations carry as much longterm consequence as the choice of what to make and what to buy and few are revisited as rarely Network footprints agreed a decade ago partners selected during a capacity crunch technology transfers completed under launch pressure these choices harden into architecture They stop looking like decisions and start looking like the...
Assessing the Impact of Tariffs on the Pharmaceutical Industry
The pharmaceutical industry function as a vital foundation for worldwide healthcare infrastructure because they push medical advancement while supporting medication availability to patients The pharmaceutical industry deals with major operational obstacles when public authorities establish tariffs for both pharmaceutical imports and exports The implementation of tariffs affects how prices shift wh...
Spleen Cytokines Against Inflammatory Bowel Disease
Over one hundred years ago at the University of Toronto Frederick Banting Charles Best and James Collip extracted protein insulin from the pancreas that saved the lives of millions of diabetics since then It is possible that the proteins extracted from the spleen can also help people with inflammatory bowel disease IBD
Digital Twins in Pharma: What They Are and Why They Matter
In the current fastpaced life sciences industry Digital Twins Pharma innovations are transforming the industrys conceptualization design testing and delivery of therapeutic products Since intelligent connected and datadriven operations have taken the center stage in pharma companies moving towards the digital age the emergence of Digital Twin Technology in Pharmaceutical structures has been a focu...
The Growing Role of Real-World Evidence in European Drug Development
For decades the randomised controlled trial has been the gold standard of pharmaceutical evidence in Europe and it still is Yet the evidence that shapes a medicines journey from laboratory to patient is no longer confined to the controlled world of the trial protocol Electronic health records disease registries insurance claims biobanks and patientreported data are now being mobilised at continent...
Navigating European Pharma Regulations: A B2B Perspective
The pharmaceutical industry in the European region practices one of the most regulating laws in the entire world Therefore regulations encompassing these areas are of prime importance for BB companies that need to achieve market entry and maintain compliance Thus this guide is meant to decompartmentalize the array of European pharma regulations and create
-
Techno Trends
Alume Biosciences Secures FDA Breakthrough Therapy Designation for Bevonescein
Alume Biosciences has received Breakthrough Therapy Designation BTD from the US Food and Drug Administration FDA for bevonescein an investigational fluorescent drug being developed to support realtime nerve visualisation during head and neck surgery in adults Bevonescein is an intravenous fluorescent peptidedye conjugate that binds to nerve tissue
-
Projects
SK pharmteco Plans More Than US$200 Million Investment in Small Molecule and Peptide Manufacturing
SK pharmteco is planning a fiveyear investment of more than US million to expand and modernise its pharmaceutical development and manufacturing operations in the United States The programme will strengthen capabilities for small molecules and peptides while supporting a more
-
Research Insights
One-month physicochemical stability study of idarubicin prepared in polyolefin-type bags for the treatment of hematological diseases
Idarubicine is a mainstay of the treatment strategy for hematological cancer The literature lacks stability data that comply with current preparation practices and recommendations for conducting stability studies
-
whitepaper
Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact
For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys
TOP ARTICLES
-
1
Assessing the Impact of Tariffs on the Pharmaceutical Industry
Kate Williamson
Pharmaceutical tariffs cause multiple adverse effects on medication costs and distribution networks and research and development activities which results in elevated healthcare expenses and treatment...
-
2
Spleen Cytokines Against Inflammatory Bowel Disease
Vladimir N Pak
Spleen cytokines regulate the immune responses through multiple pathways, contributing to a normal function of the immune system. They have been successfully used to treat and heal stomach ulcers in b...
-
3
Digital Twins in Pharma: What They Are and Why They Matter
Kate Williamson
Digital twins in Pharma are revolutionizing drug development, bioprocessing, and personalized medicine through the development of dynamic virtual replicas of the physical system. These smart models op...
-
4
The Growing Role of Real-World Evidence in European Drug Development
Lakshmi
Real-world evidence has moved from the margins of European pharmaceutical regulation to the centre of decision-making. Federated data networks, the European Health Data Space and joint clinical assess...
-
5
Navigating European Pharma Regulations: A B2B Perspective
Kate Williamson
Navigating European pharmaceutical regulations can be complex for B2B companies. This guide helps to facilitate for instance aspects like marketing authorization, clinical trials and pharmacovigilance...
press releases Read more...
Orvida Pharma Announces FDA Acceptance of KM-023 (ontivatrep) into Rare Disease Evidence Principles Process for Olmsted Syndrome
Orvida Pharma a clinicalstage biotechnology company developing first and bestinclass treatments for rare and severe genetic skin diseases today announced that the US Food and Drug Administration FDA has accepted KM ontivatrep the Companys lead oral investigational therapy for Olmsted syndrome
Sapreme Therapeutics announces oral presentation of new preclinical data on lead Duchenne muscular dystrophy candidate SPM-2551 at OTS 2026
Sapreme Therapeutics a biotechnology company developing nextgeneration RNA therapeutics for patients with genetically driven diseases today announces the oral presentation of new preclinical data from its lead Duchenne muscular dystrophy DMD programme SPM at the nd Annual Meeting of the Oligonucleot...
Oorja Bio Announces Initiation of ORBIT-IPF Phase 2 Clinical Trial Evaluating ORJ-001 for the Treatment of Idiopathic Pulmonary Fibrosis
Oorja Bio Inc a clinicalstage biopharmaceutical company developing groundbreaking therapies for fibrotic and cardiopulmonary diseases today announced that the first patient has been screened in its ORBITIPF Phase clinical trial evaluating ORJ for the treatment of idiopathic pulmonary fibrosis
Tenvie Therapeutics Announces First Subject Dosed in Phase 1 Trial of TNV313, Expanding Its Fully CNS-Penetrant NLRP3 Franchise
Tenvie Therapeutics a clinicalstage biotechnology company developing precisionengineered small molecule therapies to transform the treatment of neurological and peripheral diseases today announced the first subject dosed in a Phase clinical study evaluating TNV a fully CNSpenetrant small molecule i...
Events Read more...
21 - 23
Oct 2026Drug Formulation & Drug Delivery 2026
Paris, France
21 - 22
Oct 2026Advance Clinical Trials and Research 2026
Paris, France
22 - 23
Oct 2026PDA Aseptic Symposium 2026
Congress Square Nakanoshima, O...
26 - 28
Oct 2026ACHEMA Middle East 2026
RICEC, Riyadh, KSA, Saudi Arab...
26 - 28
Oct 2026World Orphan Drug Congress
RAI, Amsterdam, Netherlands
27 - 28
Oct 2026Pharma Manufacturing & Automation Convention 2026
Novotel Hyderabad Airport, Ind...
28 - 30
Oct 2026BIOPLUS-INTERPHEX KOREA 2026
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
LATEST NEWS Read more...
Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors
Vir Biotechnology Inc announced a collaboration and license agreement with Gilead to discover and engineer three novel PROXTEN dualmasked Tcell engager TCE development candidates targeting selected solid tumorassociated antigens Gilead will have an exclusive license to develop and commercialize
Genezen and Galibra Neuroscience Partner to Advance Gene Therapy for SSADH Deficiency Toward First-in-Human Trial
Genezen a gene therapy contract development and manufacturing organization CDMO and Galibra Neuroscience a biotechnology company developing transformative therapies for rare neurological disorders today announced a manufacturing partnership to advance Galibras GAL program an AAVbased gene therapy fo...
Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
Zealand Pharma AS a biotechnology company transforming the future of metabolic health today announced a multitarget strategic collaboration with Generate Biomedicines Inc Under the collaboration the companies intend to design and develop multispecific protein therapeutics
Enodia Therapeutics announces research and licensing collaboration agreement with Pfizer to develop small molecules directed against Sec61
Enodia Therapeutics a biotech company specializing in the development of innovative therapies with small molecules for the selective degradation of proteins at the point of synthesis today announced the signing of a collaborative research and licensing agreement with Pfizer
Catalent and Mantra™ Announce Commercial Supply Agreement for Single-Serve Oral Gel Portfolio
Catalent Inc the leading global contract development and manufacturing organization CDMO dedicated to helping people live better and healthier lives and Mantra a consumer health company developing singleserve over the counter OTC oral gel products for everyday relief
Amphista Therapeutics Announces First Patient Dosed in AMX-883 Phase 1 Clinical Trial for Acute Myeloid Leukemia
Amphista Therapeutics Limited a leader in the discovery and development of noncereblon VHL targeted protein degradation TPD medicines today announced dosing of the first patient in a Phase trial for its lead candidate AMX Initiated following authorization from the US Food and Drug Administration i...




